The British Journal of Psychiatry (2009) 195: 488-491. doi: 10.1192/bjp.bp.109.064220
© 2009 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Di Forti, M.
Right arrow Articles by Murray, R. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Forti, M.
Right arrow Articles by Murray, R. M.

High-potency cannabis and the risk of psychosis

Marta Di Forti, MD, MRCPsych, Craig Morgan, MSc, PhD, Paola Dazzan, MSc, PhD, MRCPsych, Carmine Pariante, MRCPsych, Valeria Mondelli, MD, PhD, Tiago Reis Marques, MD, Rowena Handley, BSc (Psychology), Sonija Luzi, BSc (Psychology), Manuela Russo, BSc (Psychology) and Alessandra Paparelli, MD

Institute of Psychiatry, London

Alexander Butt, MD, MRCPsych

Springfield University Hospital, St George’s and South West Thames NHS Trust, London

Simona A. Stilo, MD, Ben Wiffen, BSc (Psychology), John Powell, MA, DPhil and Robin M. Murray, MD, DSc, FRCP, FRCPsych, FMedSci

Institute of Psychiatry, London, UK

Correspondence: Correspondence: Dr Marta Di Forti, Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK. Email: m.diforti{at}iop.kcl.ac.uk

Declaration of interest

None.

Background

People who use cannabis have an increased risk of psychosis, an effect attributed to the active ingredient {Delta}9-tetrahydrocannabinol ({Delta}9-THC). There has recently been concern over an increase in the concentration of {Delta}9-THC in the cannabis available in many countries.

Aims

To investigate whether people with a first episode of psychosis were particularly likely to use high-potency cannabis.

Method

We collected information on cannabis use from 280 cases presenting with a first episode of psychosis to the South London & Maudsley National Health Service (NHS) Foundation Trust, and from 174 healthy controls recruited from the local population.

Results

There was no significant difference between cases and controls in whether they had ever taken cannabis, or age at first use. However, those in the cases group were more likely to be current daily users (OR = 6.4) and to have smoked cannabis for more than 5 years (OR = 2.1). Among those who used cannabis, 78% of the cases group used high-potency cannabis (sinsemilla, ‘skunk’) compared with 37% of the control group (OR 6.8).

Conclusions

The finding that people with a first episode of psychosis had smoked higher-potency cannabis, for longer and with greater frequency, than a healthy control group is consistent with the hypothesis that {Delta}9-THC is the active ingredient increasing risk of psychosis. This has important public health implications, given the increased availability and use of high-potency cannabis.


Related articles in BJP:

Highlights of this issue
Kimberlie Dean
BJP 2009 195: A20. [Full Text]  



eLetters:

Read all eLetters

Sample bias may obscure results
Euan M Lawson
BJP Online, 6 Jan 2010 [Full text]
Reply to letter titled: Sample bias may obscure results
Marta M Di Forti, et al.
BJP Online, 27 Jan 2010 [Full text]